Physician profile
Jonathan Flores
NPI 1134417298
$4,361.39
in general payments reported to CMS, 2019-2025
31 companies · $15.28 in 2025
The $15.28 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,550 · 2022: $2,150 · 2023: $437 · 2024: $210 · 2025: $15.28.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $662.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $662.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $1,048.55 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $637.90 | 2021-2023 | Farxiga |
| Novo Nordisk INC | $553.80 | 2021-2023 | Wegovy, Ozempic |
| Allergan, INC. | $430.34 | 2021-2022 | |
| Abbvie INC. | $420.66 | 2021-2023 | |
| Lilly USA, LLC | $202.47 | 2021-2024 | Zepbound, Mounjaro, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $118.99 | 2021 | |
| Astellas Pharma US INC | $118.14 | 2021-2024 | Veozah |
| Idorsia Pharmaceuticals US INC | $108.68 | 2022-2023 | Quviviq |
| Biohaven Pharmaceuticals, INC. | $100.38 | 2021 | |
| Antares Pharma, INC. | $70.48 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.03 | 2021-2023 | Jardiance |
| Amgen INC. | $54.49 | 2021 | |
| Merck Sharp & Dohme LLC | $53.47 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $42.20 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $39.51 | 2023-2025 | Trelegy Ellipta, Shingrix |
| Sanofi-Aventis U.S. LLC | $35.93 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.34 | 2021 | |
| Medtronic, INC. | $33.34 | 2021-2023 | Intellis Adaptivestim |
| Dexcom, INC. | $31.21 | 2021 | |
| Novartis Pharmaceuticals Corporation | $24.63 | 2021 | |
| Edwards Lifesciences Corporation | $23.39 | 2022 | |
| Endo Pharmaceuticals INC. | $17.51 | 2021 | |
| Supernus Pharmaceuticals, INC. | $16.86 | 2021 | |
| Abbott Laboratories | $15.22 | 2023 | Freestyle Libre 3 |
| Paratek Pharmaceuticals, INC. | $13.96 | 2023 | Nuzyra |
| Lucid Diagnostics INC. | $13.53 | 2023 | |
| Lundbeck LLC | $12.91 | 2023 | Vyepti |
| Adlon Therapeutics L.P. | $11.26 | 2021 | |
| Genentech USA, INC. | $11.11 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $11.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Flores listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.